Acute renal toxicity associated with suramin in the treatment of prostate cancer.
The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52-year-old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.
Figg
W D
WD
Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Cooper
M R
MR
Thibault
A
A
Headlee
D
D
Humphrey
J
J
Bergan
R C
RC
Reed
E
E
Sartor
O
O
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood / Q000652:urine; D005485:Flutamide / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007668:Kidney / Q000187:drug effects*; D016729:Leuprolide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D013498:Suramin / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics
D013498:Suramin; D005485:Flutamide; D003404:Creatinine; D016729:Leuprolide; D006854:Hydrocortisone